cdr

Hot Keywords
Drug Resistance Mechanisms Epigenetic Resistance in Cancer Therapy Biomarkers Pharmacogenetics of Cancer Liquid Biopsy Targeted Cancer Therapy Non-coding RNAs Kinase Inhibitors ABC Transporters

Top
Topic: Curcumin, the Golden Spice, as a Therapeutic Agent to Overcome Drug Resistance in Cancer Treatment: Current Insights and Future Perspectives

A special issue of Cancer Drug Resistance

ISSN 2578-532X (Online)

Submission deadline: 31 Oct 2022

Guest Editor(s)

  • Dr. Vicenç Ruiz de Porras
    Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Ctra. Can Ruti-Camí de les Escoles s/n, Badalona, Spain.

    Website | E-mail

Special Issue Introduction

Curcumin - the golden spice - is a hydrophobic polyphenol that constitutes the major curcuminoid in the spice turmeric (77% curcumin, 17% demethoxycurcumin and 3% bis-demethoxycurcumin), and is derived from the rhizome of the herb Curcuma longa. Used for centuries in the Ayurveda medicine, its demonstrated anticancer properties and low toxicity profile made it the focus of hundreds of preclinical and clinical investigations in several tumor types. Many of these anti-tumoral properties have been attributed to its role as an anti-inflammatory and anti-oxidant, or its ability to modulate the cell cycle and pathways involved in proliferation, apoptosis, migration, invasion, angiogenesis and metastasis. So far, we know that it can be combined with several anti-cancer agents in a safe and synergistic way, thereby overcoming drug resistance. Regretfully, its poor bioavailability has been one of the main issues for its successful introduction in the clinic. Nevertheless, a plethora of new formulations with a huge increase in bioavailability are under study with promising results.

This Special Issue of Cancer Drug Resistance, therefore, encompasses original and review articles on the molecular mechanisms of action of curcumin to overcome anti-tumoral therapy resistance, novel curcumin-based therapeutic strategies, new clinical approaches, as well as new biomarkers predicting response to curcumin treatment.

Submission Deadline

31 Oct 2022

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://cdrjournal.com/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=CDR220414
Submission Deadline: 31 Oct 2022
Contacts: Belinda Zhang, Assistant Editor, Belinda@cdrjournal.com

Published Articles

This special issue is now open for submission.
© 2016-2022 OAE Publishing Inc., except certain content provided by third parties